BBOT Announces New Clinical Data Advancing Its Portfolio of Three Innovative and Differentiated RAS and PI3Kα Pipeline Programs

Core Insights - BridgeBio Oncology Therapeutics, Inc. (BBOT) announced positive preliminary safety and antitumor data for its three small molecule RAS and PI3Kα programs, including BBO-8520, BBO-11818, and BBO-10203 [1][2] BBO-8520 Findings - BBO-8520 demonstrated a 65% objective response rate (ORR) and a 66% six-month progression-free survival (PFS) in patients with KRAS mutant non-small cell lung cancer (NSCLC) [3][9] - The safety profile of BBO-8520 was generally well-tolerated, with no dose-limiting toxicities (DLTs) and no grade ≥4 treatment-related adverse events (TRAEs) reported [9][15] - In combination with pembrolizumab, BBO-8520 showed promising efficacy, with all patients experiencing tumor reduction regardless of PD-L1 status [9][15] BBO-11818 Findings - BBO-11818 showed early anti-tumor activity, including a confirmed partial response in a patient with pancreatic ductal adenocarcinoma (PDAC) and a 56% tumor reduction [9][10] - The monotherapy treatment appeared generally tolerable with no DLTs and primarily gastrointestinal-related TRAEs [9][10] - Ongoing studies are evaluating BBO-11818 in heavily pretreated patients with KRAS mutant solid tumors [6][9] BBO-10203 Findings - BBO-10203 demonstrated a differentiated safety profile with no observed hyperglycemia and no DLTs [15] - The recommended go-forward dose for BBO-10203 is 500 mg, with combination studies initiated in colorectal cancer and breast cancer [10][15] - Clinical benefits were observed in heavily treated patients with colorectal cancer and hormone receptor-positive breast cancer [15] Upcoming Catalysts - BBOT plans to provide additional data updates for BBO-8520, BBO-11818, and BBO-10203 in the second half of 2026 [12][15] - Combination studies with BBO-10203 and other product candidates are expected to open later in 2026 [15]